Located at the Eastern edge of the Venetian Empire and the Western edge of the Ottoman Empire, early modern Crete and Cyprus have been at the periphery of musicology. As spaces of coloniality and shifting hegemonies, shared by acoustic communities with very different histories, this area has been ill-served by traditional methods. Sources amenable to philological and archival research are scarce, and a paradigm built around composers and institutions has so far failed to capture the lived historical realities of a complex intercultural situation. SONICC investigates long-standing processes of friction and hybridisation based on different sounds, noises, musical practices and languages, that affected local Greek, Ottoman, Jewish, Armenian, Arab and Italian populations. The project will approach this complex topic via two strands of methodological innovation. First, drawing on the emerging fields of Sound Studies and Auditory History to address sound as a distinct historical category with a key role in identity formation, using state-of-the art critical approaches to investigate Mediterranean sonic identities through decolonial and global history perspectives. Second, an intermedial approach investigating literary, visual, material and architectural materials as sources for the history of sounds and musics, as well as archival and notated music sources. Dr Hatzikiriakos has a strong track record in the study of musical identities, and is skilled with primary sources in Italian, Greek and Latin. At Sheffield, he will work with Prof Tim Shephard, a prominent authority on early modern musical identities and visual and material sources in musicology; and Dr Erin Maglaque, a leading expert on Venetian colonies. Secondments at the Orient-Institut Istanbul and the University of Athens will meet training and research needs. The MSCA will establish Dr Hatzikiriakos as an independent voice advancing global and decolonial approaches to early modern musical identities.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

The existence of fat inside bones is known since hundred years, but it is much more recently that Medullar Adiposity (MedAd) aroused the interest of researchers, as illustrated by the increasing number of publications over the last years. MedAd is anatomically separate from other fat depots, and its functions appear different (e.g. MedAd paradoxically increases during starvation). For these reasons MedAd is sometimes presented as a "new tissue" dispersed within the skeleton, and involved in the pathogenesis of several chronic diseases. On a fundamental point of view, the emergence of this new research field is based on several arguments such as: the observed correlation between low bone mass and increased MedAd; marrow adipocytes and osteoblasts differentiate from a common mesenchymal precursor stem cell; the secretion of numerous adipokines in the bone microenvironment; the modifications of MedAd with aging and diabetes; the involvement of MedAd in the development of malignant bone diseases ; the role of MedAd as regulator of haematopoietic microenvironment. The medical challenge is based on the frequency and on the impact of pathologies in which Med Ad seems to be involved. In Europe, osteoporosis affects 22 million women, a million people suffer each year from bone metastases, the prevalence of type 2 diabetes is around 4.6% and that of obesity over 20% in many European countries. The study of MedAd raises new pathophysiological and therapeutic prospects in these diseases. Several European teams currently study MedAd, using various approaches and competences. The synergy of these approaches shall provide outcomes for the scientific challenges arising from this emerging field, such as to quantify and characterize MedAd in order to improve the management of patients suffering from osteoporosis, metabolic diseases, and malignant bone diseases; to define biomarkers of MedAd activity in chronic diseases and in aging; to target MedAd in osteoporosis, obesity or prostate bone metastasis. In this context, the first international meeting on MedAd ("First European Meeting on Bone Marrow Adiposity" bma2015) has been organized by the coordinator of this MRSEI proposal, and will take place in Lille, France in August 2015. This meeting (http://bma2015.sciencesconf.org) will bring together major teams working on this emerging topic, mainly in Europe (attendees from 13 different European countries) and North America. Bma2015 wants to mark the beginning of a European network on MedAd research. The European structuration of this emerging field will be discussed during the meeting (Session 7: "Towards a European cooperative network"). Given the novelty, the potential scientific and technical breakthroughs, and the necessary cross-disciplinarity of this emerging field, we plan in priority to apply to the program "Horizon 2020, Future and Emerging Technologies FET-OPEN 1: FET-Open Research and Innovation Actions", which we aim to submit in September 2017. The objective of this proposal "BONE Adiposity in Health and Diseases" is to take the opportunity of this conference to launch a European network dedicated to MedAd research, in order to successfully address the challenge of establishing new paradigm, and to maximize the chances to succeed to the FET-OPEN call. The scientific goal of this future European application will be to solve the main issues faced by this new area, to explore its medical and technological applications, to improve human health, and to establish a European leadership in this emerging field. This MRSEI funding will support networking actions to approach new partners, essential to strengthen the competitiveness of the consortium. Furthermore, it will give the consortium the opportunity to elaborate together the European application, by supporting dedicated meetings. Finally, this timely MRSEI funding will allow the PMOI Lab to consolidate the leadership of the consortium building up around the bma2015 conference.